Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses determining cost effectiveness of novel treatments, such as immuno-oncology agents, and potential solutions to reducing financial toxicity in cancer care.
Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses determining cost effectiveness of novel treatments, such as immuno-oncology agents, and potential solutions to reducing financial toxicity in cancer care.
Transcript
In what ways would the current standard survival modeling be inadequate for determining cost effectiveness of novel treatments that cure or produce substantially longer term responses?
Standard survival modeling relies on the distribution of survival that can be easily modeled with common functional forms. And what we’re learning with some of the new immuno-oncology agents is that there can be, in some cases, a fraction of patients who have long-term responses, and in effect, cures, such that their survival approach is that of the normal population without the disease. These are very hard to capture—essentially impossible to capture—with standard survival modeling techniques, so cure model fractions were developed to try to address this problem.
With the cost of cancer steadily increasing, what, if any, solutions do you see that could reduce financial toxicity?
I do have hope that value-based pricing or performance-based pricing might be one way to address the problem of financial toxicity. I think it's also important for the insurance community, which is turning more of the cost of care over to patients, understand that for oncology this is creating tremendous burdens. So it will be a variety of solutions, both on the payer side, on the manufacturer side, and also on the physician and patient side to make better decisions so that problem is mitigated.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More